Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng(National Taiwan University Hospital), Shukui Qin, Masafumi Ikeda(National Cancer Center Hospital East), Peter R. Galle(Johannes Gutenberg University Mainz), Michel Ducreux(Institut Gustave Roussy), Tae‐You Kim(Seoul National University), Ho Yeong Lim(Samsung Medical Center), Masatoshi Kudo(Kindai University), В. В. Бредер(Russian Cancer Research Center NN Blokhin), Philippe Merle(Hôpital de la Croix-Rousse), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Daneng Li(City of Hope), Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang(Roche (China)), Lindong Li(Roche (China)), Andrew X. Zhu(Harvard University), Richard S. Finn(University of California, Los Angeles)
Cited by 1,594Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis